China approved human trial of two COVID-19 vaccines

China approved human trial of two COVID-19 vaccines China has approved the start of clinical trials of two inactivated vaccines against the new coronavirus pneumonia COVID-19.

As it became known on Tuesday, thanks to the mechanism of joint prevention and control of COVID-19 at the State Council of China, vaccines were developed by the Wuhan Institute of Biological Products under the Chinese State Pharmaceutical Corporation Sinopharm and the Beijing research company Sinovac. To date, the start of a clinical trial of vaccines has already been launched.

This is China's first batch of inactivated COVID-19 vaccines to be approved for human trials. Vaccines obtained after the elimination of pathogenic microorganisms to increase immunogenicity have the advantages of a mature manufacturing process, controlled quality standards and a wide range of clinical uses.

They can be used for mass vaccination. Their safety and effectiveness can be evaluated according to generally recognized international standards.

China has a solid foundation for the development of inactivated vaccines that are widely used in the treatment of hepatitis A, influenza, hand-foot-mouth syndrome, and polio.

Developers of new vaccines have large-scale production capacities and are ready to meet the urgent need for these vaccines in accordance with relevant legislation.